-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hematoma volume is an important determinant of prognosis after cerebral hemorrhage
Heart blood vessels
According to the post-hoc analysis of the intracerebral hemorrhage deferoxamine treatment trial (i-DEF); participants were classified according to baseline hematoma volume (small <10 mL, medium 10-30 mL, large> 30 mL)
291 subjects were included in the treatment analysis; 121 patients were small, 114 patients were medium, and 56 patients were large hematomas
According to the size of the hematoma, treatment has different effects on the outcome on day 180 (P=0.
It can be seen that in patients with moderate hematoma volume, the proportion of patients treated with deferoxamine to reach the modified Rankin scale score of 0-2 is greater than that of patients treated with placebo
Among patients with moderate hematoma volume, deferoxamine-treated patients achieved a greater proportion of modified Rankin scale scores of 0-2 than placebo-treated patients
Original source:
Chenchen Wei.